FDA Accepts BLA for Migraine Treatment, Grants Fast Track Designation for Development Program
- FDA Accepts Biologics License Application for Fremanezumab with Priority Review for Prevention of Migraine and Grants Fast Track Designation for Cluster Headache Development Program. Teva Pharmaceutical Industries Ltd. Available from: http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsArticle&ID=2323126. Published December 18, 2017. Accessed December 22, 2017.